Multidrug resistance in cancer: role of ATP–dependent transporters

By Michael M. Gottesman, T. Fojo, S. Bates. Nature Reviews. Cancer, 2002

5,538 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/6d974ee3027e35e3b781409bb23391ea76dbacdd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. O. Farokhzad
2. M. Clarke
3. D. Holtzman
4. Berislav Zlokovic
5. M. Wicha
6. A. Sagare
7. R. Deane
8. Irving L. Weissman

In Oncology

1. Berislav Zlokovic
2. M. Clarke
3. M. Wicha
4. D. Holtzman
5. K. Borden
6. H. Zahreddine
7. J. Shim
8. Bowen Du

In Surgery

1. R. Deane
2. D. Holtzman

Citations in the corpus

• ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. (2005, background): “MDR can result from several distinct mechanisms, including alterations of tumor cell cycle checkpoints, impairment of tumor apoptotic pathways, repair of damaged cellular targets, and reduced drug accumulation in tumor cells (1).”
• The therapeutic promise of the cancer stem cell concept. (2010, background): “Such strategies often have limited efficacy because of intrinsic or acquired drug resistance and/or resistance to ionizing radiation (86).”
• Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer (2016, background): “At least three members of ABC transporter family, including MDR1 (also known as P-glycoprotein and ABCB1), MDR-associated protein 1 (MRP1; also known as ABCC1) and breast cancer resistance protein (BCRP; also known as ABCG2) are known to be involved in drug resistance [48].”
• P-glycoprotein: from genomics to mechanism (2003, background): “Subsequently, other members of this family of transporters such as MRP1 (ABCC1) and MXR (ABCG2) have been shown to be capable of conferring MDR by virtue of energydependent drug efflux (reviewed in Litman et al., 2001; Borst and Elferink, 2002; Gottesman et al., 2002).”
• Molecular mechanisms of drug resistance (2005, background): “Alterations in drug efflux due to ABC transporter proteins such as P-glycoprotein (P-gp) and multidrug resistance protein (MRP) have been demonstrated in vitro [7,8].”
• Targeting multidrug resistance in cancer (2006, background): “Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
• Mechanisms and insights into drug resistance in cancer (2013, background): “Among the 48 known ABC transporters in humans, elevation of three members, P-gp (MDR1 gene product), Multidrug resistance-associated protein 1 (MRP1) and mitoxantrone resistance protein [MXR; also known as breast cancer resistance protein (BCRP) or placenta ABC protein (ABCP)], have been correlated ”